N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide
Zaleplon is a short-acting sedative from the pyrazolopyrimidine group, primarily used for the treatment of sleep disorders. It acts as an agonist at the GABA-A receptor, thereby enhancing the inhibitory effect of the neurotransmitter GABA. Due to its short half-life, it is preferred for sleep initiation. The risk of dependence and side effects is moderate, especially with prolonged use.
Translation in progress
This section is currently being translated. Content will be available soon.
View German version →Receptor Targets
Mechanism of Action
Designations
IUPAC: N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide
Legal Status
Legal status not verified by official sources. Please check current legislation independently.
Information without guarantee. Not legal advice.
Synapedia Evidence
Effects & Pharmacology — Translation in progress
This section is being translated. Content is available in German.
View in German →Total duration 4-6 hours
Peak
1-2 hours
Onset
15-30 minutes
Total duration
4-6 hours
After effects
1-2 hours
Start low. Individual sensitivity varies.
Dose sensitivity varies greatly between individuals. Body weight, tolerance, route of administration, combinations, and pre-existing conditions significantly affect outcomes. These figures are not dosing recommendations — they describe reported ranges, not safe amounts.
Risks
Summary
Zaleplon kann zu Abhängigkeit führen und hat potenzielle Wechselwirkungen mit anderen Substanzen.
Safer Use
The risks listed may be incomplete. Especially for research chemicals and rare substances, available data is limited.
Interaction details from the knowledge layer are still being translated.
Interaction data is based on known mechanisms. Unknown or rare interactions are possible and may be life-threatening.
Based on substance class, receptors, mechanisms, and effect profile.
This information is for scientific and harm-reduction purposes only. It does not constitute medical advice.
Share a report, observation, or question about this substance. Entries are reviewed before publication and marked as unverified community signals.
These entries are submitted by users and are not verified. They may contain subjective experiences, observations, source leads, or corrections. They do not replace scientific data and are not consumption advice.
The signal hub collects approved risk signals, experience reports and source leads by relevance.